Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2019 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
VAXCYTE INC | 7 | Q3 2023 | 4.8% |
CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR/A | 2023-02-07 |
13F-HR | 2023-02-03 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-10 |
13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.